ICON Awarded Best CRO at World Vaccine Congress 2017

ICON recognised for continually setting standards of excellence in vaccine development

Dublin, Ireland, 12 April 2017 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded Best Clinical Research Organisation at the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place in Washington this week.

Read More

Almac to Exclusively Share Global Expertise in EU Product Launch Workshop

Craigavon, N.I., 15 March 2017 – Almac Group, the global contract development and manufacturing organisation, is delighted to announce a free, one-day exclusive knowledge sharing workshop entitled ‘Considerations for EU Product Launch’ on Thursday 11 May 2017 at The Carlton Hotel Dublin.

This complimentary workshop will discuss key aspects regarding launching a product into Europe with a focus on niche and orphan drugs and will include:

• European regulatory framework
• The importance of the role of the Qualified Person (QP)
• Key considerations for packaging, selection and design
• Strategies for stock optimisation
• Managing a complex EU supply chain
• Considerations for a temperature sensitive product

Read More

Insights and Innovation Presented regarding a Range of Clinical Trial Supply Topics

Craigavon, N.I., 14 Mar 2017 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced that a number of its key clinical supply experts will deliver presentations at leading global conferences throughout March and April.

Heather Bogle, Supply Chain Solutions Manager will speak at this years’ Clinical Trial Supply Europe Conference being held in Barcelona, 15-16 Mar 2017. Her presentation, entitled “Regulatory Impact: Technology, Tools, and Insight to Mitigate Risk”, will take place at 4pm on day one of the conference where she will share the stage with a growing list of other industry experts from across the globe.

Read More

ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials

Long-time IABCN members and former Ambassador Award honorees, ICON plc, global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has been selected by the US FDA to validate three Patient Reported Outcomes (PRO) instruments that will measure clinical endpoints in antibacterial drug trials. This is the 2^nd time ICON has been selected by the FDA to create industry-standard PRO measures.
Read More